Oric Pharmaceuticals Inc (ORIC)
NASDAQ:ORIC
Want to see ORIC full AI Analyst Report?
Total Valuation
Oric Pharmaceuticals has a market cap or net worth of $870.58M. The enterprise value is $819.36M.
Market Cap$870.58M
Enterprise Value$819.36M
Share Statistics
Oric Pharmaceuticals has 103,517,560 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding103,517,560
Owned by Insiders1.05%
Owned by Institutions72.23%
Financial Efficiency
Oric Pharmaceuticals’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -36.30%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)-36.30%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee0.00
Profits Per Employee-1.06M
Employee Count122
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Oric Pharmaceuticals is ―. Oric Pharmaceuticals’s PEG ratio is 0.28.
PE Ratio―
PS Ratio0.00
PB Ratio1.87
Price to Fair Value1.87
Price to FCF-6.30
Price to Operating Cash Flow-8.05
PEG Ratio0.28
Income Statement
In the last 12 months, Oric Pharmaceuticals had revenue of 0.00 and earned -129.47M in profits. Earnings per share was -1.47.
Revenue0.00
Gross Profit-1.22M
Operating Income-143.00M
Pretax Income-129.47M
Net Income-129.47M
EBITDA-128.25M
Earnings Per Share (EPS)-1.47
Cash Flow
In the last 12 months, operating cash flow was -110.88M and capital expenditures -487.00K, giving a free cash flow of -111.36M billion.
Operating Cash Flow-110.88M
Free Cash Flow-111.36M
Free Cash Flow per Share-1.08
Dividends & Yields
Oric Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change42.18%
50-Day Moving Average10.08
200-Day Moving Average10.85
Relative Strength Index (RSI)38.88
Average Volume (3m)1.45M
Important Dates
Oric Pharmaceuticals upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Oric Pharmaceuticals as a current ratio of 14.13, with Debt / Equity ratio of 0.00%
Current Ratio14.13
Quick Ratio14.13
Debt to Market Cap0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Oric Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Oric Pharmaceuticals EV to EBITDA ratio is -5.33, with an EV/FCF ratio of -6.00.
EV to Sales0.00
EV to EBITDA-5.33
EV to Free Cash Flow-6.00
EV to Operating Cash Flow-6.03
Balance Sheet
Oric Pharmaceuticals has $281.93M in cash and marketable securities with $0.00 in debt, giving a net cash position of $281.93M billion.
Cash & Marketable Securities$281.93M
Total Debt$0.00
Net Cash$281.93M
Net Cash Per Share$2.72
Tangible Book Value Per Share$4.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Oric Pharmaceuticals is $20.89, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$20.89
Price Target Upside94.32% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast―
EPS Growth Forecast23.91%